<code id='4253237F33'></code><style id='4253237F33'></style>
    • <acronym id='4253237F33'></acronym>
      <center id='4253237F33'><center id='4253237F33'><tfoot id='4253237F33'></tfoot></center><abbr id='4253237F33'><dir id='4253237F33'><tfoot id='4253237F33'></tfoot><noframes id='4253237F33'>

    • <optgroup id='4253237F33'><strike id='4253237F33'><sup id='4253237F33'></sup></strike><code id='4253237F33'></code></optgroup>
        1. <b id='4253237F33'><label id='4253237F33'><select id='4253237F33'><dt id='4253237F33'><span id='4253237F33'></span></dt></select></label></b><u id='4253237F33'></u>
          <i id='4253237F33'><strike id='4253237F33'><tt id='4253237F33'><pre id='4253237F33'></pre></tt></strike></i>

          hotspot

          hotspot

          author:explore    Page View:8431
          Richard Burr
          North Carolina Senator Richard Burr received strong support from the biotech sector. Gerry Broome/AP

          WASHINGTON — A veteran senator and champion of the biotech sector beat back an unusually strong challenge Tuesday night — thanks in large part to loyal support from the industry.

          North Carolina Senator Richard Burr, a Republican who has long protected the bioscience companies that drive his state’s economy, overcame a surprisingly robust challenge from Democratic candidate Deborah K. Ross.

          advertisement

          Burr, now finishing his second term in the Senate, serves on committees with oversight of both the Food and Drug Administration and Medicare and Medicaid. He is also chairman of the Select Committee on Intelligence.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          leisure time

          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more
          FDA panel endorses Alnylam’s heart drug — after picking it apart
          FDA panel endorses Alnylam’s heart drug — after picking it apart

          KristofferTripplaar/SipaUSA/APAgroupofadviserstotheFoodandDrugAdministrationvotedinfavorofAlnylamPha

          read more
          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more

          Hearing on Medicare drug price negotiation gets unusually heated

          AtaWednesdayhearing,OversightsubcommitteeChairMorganGriffith(R-Va.)mockedMedicaredrugpricenegotiatio